SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_______________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
__________________________________
Date of Report (Date of earliest event reported): October 20, 1998
SELFCARE, INC.
(Exact name of Registrant as specified in charter)
Delaware 0-20871 04-3164127
- - --------------------------- ---------------- ------------------
(State or other jurisdiction (Commission file) (IRS employer
of incorporation) number) identification no.)
200 Prospect Street, Waltham, Massachusetts 02453
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
(781) 647-3900
(Registrant's telephone number, including area code)
There are 3 pages in this Report.
Page 1 of 3
Item 5. Other Events
On October 20, 1998, the Company released the attached
announcement regarding a complaint against the Company filed by
Abbott Laboratories regarding an alleged patent infringement.
Item 7. Financial Statements, Pro Forma Financial Information
and Exhibits
99.1 Press Release dated October 20, 1998.
Page 2 of 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the Registrant has duly caused this report to be
signed on its behalf by the undersigned thereunto duly
authorized.
Date: October 22, 1998
SELFCARE, INC.
/s/ Kenneth D. Legg
--------------------
Kenneth D. Legg
Vice President, U.S. Operations and
Secretary
Page 3 of 3
EXHIBIT 99.1 Press Release dated October 20, 1998
Selfcare Addresses Recent Patent Claim
Tuesday, October 20, 1998 04:57 PM
WALTHAM, Mass., Oct. 20 /PRNewswire/ -- Selfcare, Inc. announced
today that Selfcare and LifeScan, Inc., a subsidiary of Johnson &
Johnson, have been served with a complaint and motion for
preliminary injunction by Abbott Laboratories alleging that the
disposable test strips used in the FastTake(TM) blood glucose
monitoring system supplied by Selfcare to LifeScan infringe a
U.S. patent issued to Abbott on October 13, 1998. Abbott is
seeking damages and an injunction against sales in the United
States. Abbott is also seeking to enjoin LifeScan and Selfcare
from the manufacture, use and sale of these blood glucose test
strips in the United States during the pendency of the
infringement litigation.
Based on a review of the Abbott claims by patent counsel,
Selfcare believes that the FastTake(TM) test strips do not
infringe the Abbott patent.
Selfcare also believes that Abbott's claims will be proven to be
without merit, and intends to vigorously defend against them.
Selfcare, with facilities in Waltham, Massachusetts; Inverness,
Scotland; Galway, Ireland; Munich, Germany; and Tel Aviv, Israel,
is engaged in the development, manufacture and marketing of
health maintenance and home self-test diagnostic products for the
diabetes, women's health and nutritional supplement markets.
Forward-looking statements in this release involve a number of
risks and uncertainties including, but not limited to, product
demand, market acceptance, changing economic conditions, risks in
product and technology development, regulatory approvals, the
effect of the Company's accounting policies, and other risk
factors detailed in the Company's Form 10-KSB and other filings
with the Securities and Exchange Commission.
SOURCE Selfcare, Inc.
CONTACT: Ron Zwanziger, Chief Executive Officer, or Doug Guarino,
Director of Communications of Selfcare, Inc., 781-647-3900; Jill
Ruja, Meredith Pudalov, or Press: Darren Brandt of Morgen-Walke
Associates, 212-850-5600, for Selfcare, Inc.
